Search E-Book

Revised Schedule M - AHU/HAVC Requirements For Sterile Pharmaceutical Manufacturing

 


A technically aligned interpretation of Revised Schedule M, Part I-A, Clauses 3.1–3.5, with reference to WHO GMP principles and international sterile-manufacturing practices.

3.1 — Segregated AHUs & Cleanroom Grade Control

Regulatory expectation:
AHUs serving sterile-product manufacturing areas shall be segregated from AHUs serving other areas. Critical areas such as aseptic filling, sterilized-component unloading and associated change rooms corresponding to Grades B, C and D require appropriate AHU segregation.

Engineering/GMP implications:
• Dedicated air-handling systems should be designed to minimize the risk of cross-contamination and unintended air transfer.
• Airflow distribution, return-air arrangement, pressure differentials and filter configuration shall be established through documented design qualification and risk assessment.
• Filtration stages should be appropriately selected to achieve the required cleanroom classification.
• HVAC design should consider HEPA filtration, air-change rate, pressure cascade, temperature/RH control and airflow visualization.

3.2 — Aseptic Filling: Grade B Background

For aseptic filling operations, the filling room shall achieve Grade B conditions at rest/unmanned.

The specified Grade B condition should be recoverable after personnel leave the room following completion of operations, with Schedule M specifying a period of approximately 30 minutes.

Critical controls include:
• Cleanroom recovery-time qualification
• Non-viable airborne particulate monitoring
• Viable environmental monitoring
• Differential-pressure monitoring
• Temperature and relative-humidity monitoring
• Airflow visualization/smoke studies
• HVAC alarm and BMS/EMS monitoring, where applicable

Under the Schedule M particulate classification historically associated with these clauses, Grade B at-rest limits are ≤35,200 particles/m³ ≥0.5 ยตm and ≤293 particles/m³ ≥5 ยตm.

3.3 — Grade A Critical Processing Zone

Aseptic filling and other critical open-product operations shall be performed under Grade A conditions.

Grade A protection may be achieved through appropriately qualified:

• Unidirectional Airflow (UDAF/LAF) systems
• HEPA-filtered airflow
• Isolator technology
• RABS / barrier technology

WHO guidance gives a UDAF velocity of approximately 0.36–0.54 m/s at the defined test position for open cleanroom applications, with airflow uniformity and effectiveness demonstrated through airflow-visualization studies.

The objective is not simply to achieve a velocity value; the system must demonstrate effective first-air protection of exposed sterile product and critical surfaces.

3.4 — Terminally Sterilized Products: Grade C Filling Environment

Where the finished product is subjected to a validated terminal sterilization process after filling and sealing, the filling room is required to meet Grade C conditions at rest under the Schedule M provision.

The room should be capable of recovering to the specified condition within approximately 30 minutes after personnel leave the area.

The HVAC system should therefore be qualified for:

• Recovery time
• Airflow pattern
• Air-change performance
• Pressure differential
• HEPA-filter integrity
• Temperature/RH control
• Particle classification

3.5 — Manufacturing & Component Preparation Areas

Manufacturing and component-preparation areas associated with sterile-product manufacture shall meet Grade C conditions as specified by Schedule M.

This includes appropriate environmental control for activities such as:

• Solution/product preparation
• Component preparation
• Washed-component handling
• Preparation before sterilization or aseptic transfer

Following preparation, washed components and vessels must be protected against recontamination through appropriate environmental controls and handling practices.


CRITICAL HVAC / CLEANROOM PARAMETERS

1. Air Changes per Hour — ACH

Schedule M specifies that Grade B and Grade C areas shall have not less than 20 air changes per hour, provided that the room has an appropriate airflow pattern and suitable HEPA filtration.

However, 20–40 ACH should not be treated as a universal regulatory acceptance range. The final design airflow should be established through room volume, heat load, personnel/equipment loading, contamination-control strategy, airflow pattern, pressure cascade and demonstrated cleanroom performance.

2. Pressure Differential

A controlled pressure cascade should be established between areas of different environmental classifications.

The cited Schedule M requirement specifies a differential pressure of at least 15 Pa between areas of different environmental standards, with suitable pressure gauges/manometers for monitoring and verification.

Pressure cascade must be supported by:

Airflow direction + room leakage control + door discipline + pressure monitoring

—not merely by setting a differential-pressure setpoint.

3. HEPA Filter Integrity Testing

HEPA filters serving critical clean areas should undergo installed filter leakage/integrity testing using an appropriate aerosol challenge and photometric or equivalent validated methodology, with acceptance criteria established in the applicable standard/SOP.

WHO guidance recommends installed HEPA filter leakage testing at approximately 6-month intervals, with the interval not exceeding 12 months, subject to the applicable regulatory and site qualification programme.

4. Airflow Visualization

Smoke studies/airflow visualization should demonstrate that airflow:

Protects the exposed product → protects critical surfaces → prevents ingress from lower-grade areas → does not create turbulence or stagnant zones.

For Grade A areas, airflow visualization is an essential part of demonstrating the effectiveness of the unidirectional airflow system.

5. Cleanroom Classification

Cleanroom classification should be established using the applicable ISO 14644 framework together with the relevant GMP requirements.

WHO sterile GMP specifies particle limits for Grades A–D and requires classification in appropriate at-rest and in-operation states, with additional consideration of critical processing locations.


GMP ENGINEERING PRINCIPLE

A compliant HVAC system is not simply an air-conditioning system.

It is a Contamination Control System designed to control:

Airflow → Filtration → Pressure Cascade → Temperature/RH → Particle Load → Microbial Risk → Cross-Contamination → Product Protection

The HVAC system should therefore be supported by documented DQ → IQ → OQ → PQ, periodic requalification, HEPA integrity testing, airflow visualization, recovery testing, pressure-differential verification and environmental monitoring.

Pharmatext.co.in — Technical Knowledge for Pharmaceutical Professionals

๐ŸŒ www.pharmatext.co.in

#Pharmatext #PharmaceuticalEngineering #RevisedScheduleM #ScheduleM #GMP #WHO_GMP #EU_GMP #Annex1 #PharmaceuticalHVAC #AHU #Cleanroom #CleanRoomTechnology #AsepticProcessing #SterileManufacturing #HEPAFilter #HEPAIntegrity #AirflowVisualization #SmokeStudy #UnidirectionalAirflow #UDAF #LAF #RABS #Isolator #PressureCascade #CleanroomQualification #HVACQualification #DQ #IQ #OQ #PQ #EnvironmentalMonitoring #ContaminationControlStrategy #CCS #PharmaceuticalManufacturing #PharmaProfessionals


Pharmaceutical Water System — From Bore Well to Purified Water

 


Water is a critical utility in pharmaceutical manufacturing—and its quality directly impacts product quality, process control, cleaning, and patient safety.

This infographic presents the typical pharmaceutical water treatment pathway, from bore-well raw water to Purified Water, covering key stages such as:

๐Ÿ”น Raw Water Storage
๐Ÿ”น Multimedia Filtration
๐Ÿ”น Activated Carbon Filtration
๐Ÿ”น Water Softening
๐Ÿ”น Micron Filtration
๐Ÿ”น Reverse Osmosis (RO)
๐Ÿ”น UV Disinfection
๐Ÿ”น Polishing / EDI
๐Ÿ”น Purified Water Storage & Distribution Loop
๐Ÿ”น Point-of-Use Filtration

A robust pharmaceutical water system should be appropriately designed, qualified, validated, monitored, maintained, and documented in accordance with applicable regulatory and GMP expectations, including USFDA, ICH Q7 and Schedule M, as applicable.

๐Ÿ’ง Ensure Purity. Ensure Compliance. Ensure Patient Safety.

๐Ÿ“š Explore more pharmaceutical knowledge at:
๐ŸŒ www.pharmatext.co.in

#PharmaceuticalWaterSystem #PurifiedWater #WaterPurification #PharmaWater #USFDA #ICH #ScheduleM #GMP #PharmaceuticalManufacturing #PharmaEngineering #WaterTreatment #ROSystem #EDI #Validation #Qualification #GMPCompliance #PharmaceuticalIndustry #PharmaProfessionals #Pharmatext #DrugManufacturing


GDUFA IV: What’s Changing for ANDA Stakeholders?


The FDA’s draft GDUFA IV Commitment Letter proposes several important enhancements to the generic drug review program for FY2028–FY2032.

Key changes include shorter priority review goals, stronger pre-submission facility correspondence (PFC), Discipline Review Letters (DRLs), improved DMF–ANDA coordination, standardized data requirements, enhanced inspection pathways, and greater performance & financial transparency.

๐ŸŽฏ The overarching objective: fewer review cycles, faster timelines, greater predictability, and stronger early engagement between FDA and generic drug applicants.

This poster provides a quick comparison of GDUFA III vs. the proposed GDUFA IV commitments for regulatory affairs, generic drug manufacturers, and ANDA stakeholders.

๐Ÿ“Œ Follow Pharmatext for pharma regulatory updates, FDA developments, and industry insights.

๐ŸŒ www.pharmatext.co.in

hashtagGDUFAIV hashtagGDUFA hashtagFDA hashtagUSFDA hashtagANDA hashtagGenericDrugs hashtagPharmaceuticalIndustry hashtagPharmaRegulatory hashtagRegulatoryAffairs hashtagFDAUpdates hashtagGenericDrugDevelopment hashtagDMF hashtagANDAReview hashtagPharmaceuticalRegulations hashtagDrugRegulatory hashtagPharmaUpdates hashtagUSFDAUpdates hashtagPharmaIndustry hashtagPharmatext hashtagPharmaRegulatoryAffairs

GxP System vs Non-GxP System — Why Does It Matter?



In the pharmaceutical industry, a computerized system is not simply an IT tool—it can directly impact product quality, data integrity, regulatory compliance, and ultimately patient safety.


Our latest comparison highlights the key differences between GxP and Non-GxP systems, including:

๐Ÿ”น Regulatory Compliance
๐Ÿ”น Data Integrity & ALCOA+ Principles
๐Ÿ”น Documentation & Record Keeping
๐Ÿ”น Quality Assurance
๐Ÿ”น Risk Management
๐Ÿ”น Change Control
๐Ÿ”น Audit & Inspection Readiness
๐Ÿ”น Training & Competency
๐Ÿ”น Patient Safety
๐Ÿ”น Business & Regulatory Impact
A properly designed, validated and controlled GxP system provides confidence that critical data remains accurate, reliable, traceable and compliant throughout its lifecycle.
๐Ÿ“Œ Know your system. Assess its GxP impact. Protect your data.

๐ŸŒ www.pharmatext.co.in
Your Partner in Regulatory Compliance & Quality Excellence

hashtagGxP hashtagGxPCompliance hashtagComputerizedSystemValidation hashtagCSV hashtagDataIntegrity hashtagALCOAPlus hashtagPharmaceuticalIndustry hashtagPharmaCompliance hashtagQualityAssurance hashtagRegulatoryCompliance hashtag21CFRPart11 hashtagGMP hashtagFDA hashtagPharmaQA hashtagValidation hashtagDataIntegrityInPharma hashtagPatientSafety hashtagPharmaTech hashtagPharmatext